Learn how Novartis compressed 39 years of computational chemistry into 9 hours with AWS, screening 10 million compounds and identifying three promising candidates for about $4,000. Novartis Institutes for Biomedical Research's (NIBR) purpose is to cure, care, and provide medicines that treat and prevent diseases, ease suffering and improve quality of life. With the average time and cost to take a drug to market being 10 years and about $1 billion, NIBR wants to reduce these numbers and they are doing this with high performance computing.
Steve manages the Scientific Computing group at NIBR specializing in the application of High Performance and Cloud Computing to advance drug discovery.
After obtaining his PhD in Chemical Crystallography in 1992, he continued his research career at the University of Calgary. During this time he was exposed to his first “super computer”-the Fujitsu VPX240, and realized the impact HPCC could have on scientific discovery. This was followed by a move to Harvard University in 1998 working under the supervision of Professors Don Wiley and Steve Harrison in the area of macromolecular and computational crystallography. Following a brief adventure into telecom startups, he came back into the scientific computing world as HPC lead at Vertex Pharmaceuticals. In 2004 he joined Novartis where he remains today as Global Lead for Scientific Computing.